ASGCT Podcast Network

A special ASGCT Annual Meeting preview episode and crossover with the Rx for Biotech podcast featuring guest hosts and ASGCT Communications Committee members Chris Leidli and Catherine Gillespie. They interview ASGCT's Molecular Therapy Scientific Editor Rory Bricker-Anthony, PhD, and preview a scientific symposium at the upcoming ASGCT Annual Meeting on the impact of generative AI on cell and gene therapy (CGT), best practices, and real-world applications for communicators.

Dr. Bricker-Anthony, a speaker in the session, shares insight into what attendees can learn from the upcoming session, including current tools and applications in AI for CGT communications.

Listen now to get a sneak peek of the upcoming symposium at the ASGCT Annual
Meeting and valuable tips for conference attendees.

ASGCT Annual Meeting: annualmeeting.asgct.org

RX for Biotech Podcast: soundcloud.com/biotechguru

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Today we have a very special guest on The Issue: Federico Mingozzi, PhD. Federico’s first ASGCT podcast could have easily been on Giants of Gene Therapy. Still, we're excited that he could join us for an in-depth chat about his career journey and AAV immunogenicity. Dr. Mingozzi has done seminal work throughout his career in AAV gene therapy, and his 2020 Molecular Therapy review of our current understanding of the immune reaction to these therapies is a must-read for anyone trying to get a handle on the very complicated landscape of immune reactions to viral vectors.

Have you registered for the ASGCT Annual Meeting yet? Meet us in Baltimore, May 7-11, for the only must-attend event in cell and gene therapy. There’s no better place to deep dive in this field than the ASGCT Annual Meeting—you will not find the same breadth or depth of CGT research anywhere in the world. Check out the full program and learn more about the meeting at www.annualmeeting.asgct.org.

Music by: https://www.steven-obrien.net/
--------------------------
Bright New Morning - Steven O'Brien

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Join Drs. Paloma Giangrande (Editor-in-Chief of Molecular Therapy Nucleic Acids and Chief Technology Officer at Eleven Therapy) and Maxim Berezovski (Professor of Bioanalytical Chemistry at the University of Ottawa). They will discuss a recent article published in Molecular Therapy Nucleic Acids by Dr. Berezovski and colleagues titled, Discovery of DNA aptamers targeting SARS-CoV-2 nucleocapsid protein and protein-binding epitopes for label-free COVID-19 diagnostics.

Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals

'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.
www.scottbuckley.com.au

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Episode 2 of The Issue on the ASGCT podcast network is an in-depth interview with Dr Tom McCauley, CSO of Omega Therapeutics. Tom and Emily talk about his path from condensed matter physics to leading teams of scientists exploring the next generation of molecular therapeutics. They also dive into their mutual experience in the early days of in vivo gene editing and the challenges one faces with the complexities of these products, particularly before there is much of a roadmap for development. Finally, they dive into the recent public Ad Comm and ultimate approval of Casgevy and how we hope the industry continues to evolve and set standards as we move forward novel approaches.

Music by: https://www.steven-obrien.net/
--------------------------
Bright New Morning - Steven O'Brien

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

This episode features a conversation between Dr. Richard Vile, Professor of Immunology at Mayo Clinic and Dr. Timothy Cripe, Editor-in-Chief of Molecular Therapy Oncology and Professor and Chief of Hematology/Oncology/BMT at Nationwide Children’s Hospital. They will discuss a recent article published in the June issue of Molecular Therapy Oncology by Dr. Vile and colleagues titled, "Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses."

Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals

'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.
www.scottbuckley.com.au

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Join Dr. Emily Walsh Martin for the first episode of her new podcast, The Issue on the ASGCT podcast network. Emily welcomes Michael Storey, PharmD (Nationwide Children's Hospital), to discuss the path from patient diagnosis to therapy administration for approved gene and cell therapies including the clinical and administrative steps along the way.

Music by: https://www.steven-obrien.net/
--------------------------
Bright New Morning - Steven O'Brien

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Welcome to the first episode of the Molecular Therapy Podcast! Join Dr. Roland Herzog, Editor-in-Chief of Molecular Therapy and Professor of Pediatrics at Indiana University, and Dr. Norbert Pardi, Assistant Professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania, as they discuss a recent article published in the September issue of Molecular Therapy by Dr. Pardi and colleagues titled, "Development of an mRNA-lipid Nanoparticle Vaccine Against Lyme Disease."

Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals

'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.
www.scottbuckley.com.au

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Note: this episode is cross-posted with the Rx for Biotech podcast, hosted by Chris Leidli. 

Emily Walsh Martin, PhD, at Tremont Therapeutics Consulting, works with gene and cell therapy companies and investors who are seeking to advance novel therapies in the clinic. ASGCT’s Policy Summit is a big deal to her: It provides a full view of the clinical pipeline and helps her guide clients past the drug approval process and into considerations of patient access, manufacturing, and insurance reimbursement.

In this special episode, Dr. Walsh Martin shares her highlights from the fifth annual Policy Summit: the chance to see top decision makers, patients, and advocates in the same room; the discussion of the recent CGT Access Model from the Centers for Medicare and Medicaid Innovation (with deputy director Laura McWright); and, of course, the first in-person speaking engagement of Nicole Verdun, MD, director of FDA CBER’s new Office of Therapeutic Products (OTP).

Hear Dr. Walsh Martin’s thoughts on patient-focused development, public access to data, and FDA’s support of platform designations for new CGT treatments. Her interviewer is Chris Leidli, host of the Rx for Biotech podcast and member of ASGCT’s Communications Committee. 

This year’s Policy Summit featured its highest-profile line-up yet—and it’s still available to view on-demand until October 23! Learn more at asgct.org/advocacy/policy-summit.

Not sure if on-demand access is worth it? Let Dr. Walsh Martin convince you why you don’t want to miss the event!

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Note: this episode is cross-posted with the Rx for Biotech podcast, hosted by Chris Leidli.

Francesca Cook is the Vice President, Pricing and Market Access, at REGENXBIO and past chair of ASGCT's Government Relations Committee. She’s attended and helped with ASGCT’s annual Policy Summit since its inception five years ago. In this episode, Cook shares her experience and advice around the event—coming up Sept. 18-19 (virtually + in Washington, DC) with its highest-profile line-up yet and more ways to interact with top CGT decision makers. Her interviewer is Chris Leidli, host of the Rx for Biotech podcast and member of ASGCT’s Communications Committee.

If you work anywhere in the field of cell and gene therapy (CGT)—science, industry, commerce, regulatory—Cook can tell you why you should register for the Policy Summit, a unique opportunity to discuss how your work can be affected by NIH, FDA, patient advocacy groups, private insurers, and more. And if you’ve already registered, we look forward to seeing you! Cook has some advice for making the most out of the event.

Learn more and register at asgct.org/PolicySummit

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.

Luigi Naldini, MD, PhD, discusses his intercontinental career and the future of gene editing and use of lentiviral vectors during a one-on-one conversation with ASGCT President Hans-Peter Kiem, MD, PhD. Welcome to the seventh episode of Giants of Gene Therapy!

Dr. Naldini is a Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. He has achieved worldwide renown as the pioneer of lentivirus gene therapy, a tool that offers hope for cures to deadly diseases.

Dr. Naldini has been a mentor to many young scientists and a prolific researcher with more than 280 publications. He has founded three biotech startups. He’s spoken in more than 150 congresses worldwide. And he’s received numerous global awards, including the Grand Officer of the Order for Merit of the Italian Republic (one of the highest-ranking honors in Italy), the Louis-Jeantet Prize for Medicine in Switzerland, and Outstanding Achievement Awards from both the American Society of Gene and Cell Therapy and European Society of Gene and Cell Therapy. 

Dr. Naldini has been an ASGCT member since 2000, the year he also attended the 3rd ASGCT Annual Meeting. He’s served on the Society’s board and committees.

Music by: Steven O'Brien
https://www.steven-obrien.net/

"Making Progress"

(Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)

Show your support for ASGCT!: https://asgct.org/membership/donate

See omnystudio.com/listener for privacy information.